Vogenx, Inc. (NASDAQ:VOGX)
| Market Cap | $176.33M-8.7% |
| Revenue (ttm) | $0 |
| Net Income | -$6.28M |
| EPS | -$0.61 |
| Shares Out | 14.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,911 |
| Open | $13.29 |
| Previous Close | $12.80 |
| Day's Range | $11.87 - $13.29 |
| 52-Week Range | $11.51 - $38.41 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 5, 2027 |
About VOGX
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Next catalysts
- Feb 5, 2027Earnings report
$VOGX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VOGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VOGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VOGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VOGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VOGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VOGX
| VXFVanguard Extended Market ETF | $1.44M |
| VTWOVanguard Russell 2000 ETF | $106.60K |
| VTWGVanguard Russell 2000 Growth ETF | $10.55K |
| VTWVVanguard Russell 2000 Value ETF | $3.97K |
| VTHRVanguard Russell 3000 ETF | $1.64K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VOGX’s recent data — informational, not investment advice
